An exemplary-damages claim — called punitive damages in most states — needs facts showing a manufacturer knew its device could seriously injure patients and sold it anyway without saying so. For a bone-growth device, the facts that do that work are documented injury reports, internal company knowledge of those reports, and evidence that the published safety record readers and surgeons relied on was shaped to look cleaner than it was.
The rhBMP-2 litigation over Medtronic's Infuse Bone Graft is the clearest worked example. Infuse is a protein-based bone-growth product implanted during spinal fusion surgery to make vertebrae knit together without a bone graft taken from the patient's hip. Its history shows both what an exemplary-damages record looks like and the federal preemption wall that has stopped most of these claims before a jury ever heard them.
Table of Contents
- What a court actually needs to see
- The adverse-event record and the off-label use
- The literature problem — the strongest conduct evidence
- The preemption wall that stops most of these claims
- What happened to the filed cases, and what a reader can do
- Frequently Asked Questions
What a court actually needs to see
Compensatory damages pay for the harm. Exemplary damages punish conduct, and most states require clear and convincing evidence of something worse than carelessness — fraud, malice, or conscious disregard of a known risk. The standard is deliberately hard to meet.
That turns the case into a question about the company's knowledge, not the patient's injury. A plaintiff has to show the manufacturer held information about a specific danger, understood what it meant, and chose not to warn doctors or patients. Three categories of proof carry most of the weight:.
- Adverse-event reports showing the injury pattern was already known
- Regulatory notices putting the use or the risk on the record
- Documents showing the company influenced what the medical literature said about its own product
The adverse-event record and the off-label use
The FDA issued a public health notification on July 1, 2008, titled "Life-threatening Complications Associated with Recombinant Human Bone Morphogenetic Protein in Cervical Spine Fusion." It stated plainly that rhBMP products — Medtronic's Infuse and Stryker's OP-1 Putty — are not FDA-approved for use in the cervical spine, the neck, and that their safety there has not been demonstrated. The same notification described 38 adverse-event reports received over roughly four years after off-label cervical use. Patients developed swelling of neck and throat tissue that caused difficulty swallowing, breathing, or speaking, and some needed emergency intervention.
Infuse's actual approval covered anterior lumbar fusion from L2 to S1 — the lower back, not the neck. The FDA notification is preserved in a federal patient-safety archive. Off-label use is legal: a surgeon may use an approved device outside its approved indication. That point matters for an exemplary-damages theory because the question is not whether the surgery was permitted, but whether the manufacturer knew the specific complications being reported and said nothing useful about them.
The literature problem — the strongest conduct evidence
The most damaging facts in the Infuse record are about the medical journals. Carragee and colleagues published "A challenge to integrity in spine publications: years of living dangerously with the promotion of bone growth factors" in *The Spine Journal* in June 2011. They reviewed 13 industry-sponsored rhBMP-2 trials covering 780 patients, every one of which reported no product-related adverse events, and concluded the original publications underestimated rhBMP-2-related harms. The Senate Finance Committee went further.
Its October 2012 staff report, the product of a 16-month Baucus–Grassley investigation that reviewed more than 5,000 Medtronic documents covering 13 Infuse studies, found that Medtronic employees helped write, edit, or shape at least 11 journal articles. The report found the company inserted language promoting Infuse over autograft — bone harvested from the patient's own hip — by emphasizing donor-site pain, and that studies reaching journals omitted serious adverse-event risks. Medtronic disputed the characterization. The company stated that it "vigorously disagrees with any suggestion that the company improperly influenced or authored any of the peer-reviewed published manuscripts discussed in the report." A disputed finding is still evidence a plaintiff can put in front of a jury; it is not a finding of liability.
The preemption wall that stops most of these claims
This is where device cases diverge sharply from drug cases. In *Riegel v. Medtronic*, 552 U.S. 312, decided 8–1 in February 2008, the Supreme Court held that the Medical Device Amendments' express preemption clause bars state common-law design and labeling claims against devices approved through premarket approval. The Court treated state tort duties as "requirements" that federal approval displaces. Infuse went through premarket approval, so *Riegel* applies to it.
In *Caplinger v. Medtronic*, 784 F.3d 1335, a 2–1 Tenth Circuit panel written by Judge Gorsuch held in April 2015 that off-label Infuse claims were preempted. The opinion noted the plaintiff offered no answer to how state law could impose a duty to revise a label that federal regulation barred Medtronic from revising. Judge Lucero dissented in part and would have let the failure-to-warn claim proceed as arguably parallel to federal requirements. The practical consequence: conduct evidence strong enough to support punitive damages does not help if the underlying claim is dismissed first. A surviving claim generally has to be framed as "parallel" — alleging the manufacturer violated a federal requirement, not that federal requirements were inadequate. Fraud and off-label promotion theories are the usual route, and they are contested in every circuit.
What happened to the filed cases, and what a reader can do
Medtronic announced on May 6, 2014 that it would pay about $22 million to resolve roughly 950 filed and unfiled Infuse claims. The company described the deal expressly as a compromise of disputed claims and not an admission of liability, and booked a charge of $120–140 million covering an estimated 3,800 further claims.
That averages to roughly $23,000 per claim in the announced group — compensation for injury, not punishment, and far below what a punitive verdict would look like. If you are evaluating a bone-growth device injury, the facts worth assembling are specific and documentary: A widely repeated figure puts Medtronic's payments to physician authors at roughly $210 million over about 15 years. That number circulates in secondary coverage of the Senate report rather than in the report text that is readily checkable, so treat it as unconfirmed and verify it against the committee's own document before relying on it in a demand letter or a pleading.
- The operative report naming the product and the exact vertebral levels treated
- Whether the implant site falls inside the device's approved indication
- Dated records of the complication — airway swelling, difficulty swallowing, uncontrolled bone growth, revision surgery
- The surgeon's financial relationship with the manufacturer, if any
- The statute of limitations in your state, which for a 2008-era implant has very likely run
Frequently Asked Questions
Is exemplary damages the same thing as punitive damages?
Yes. Texas and a few other states use "exemplary," most use "punitive," and both describe money awarded to punish conduct rather than to compensate a loss.
Does off-label use by my surgeon defeat a claim against the manufacturer?
No, but it complicates it. Off-label use is legal, and the claim targets what the manufacturer knew and disclosed — though *Caplinger* shows courts have still found off-label Infuse claims preempted.
Can I still file over an rhBMP-2 injury from a 2009 surgery?
Almost certainly not. State limitations periods for product-liability injury typically run two to four years from discovery, and the 2014 settlement closed the large filed group.
You Might Also Like
- A Hip Implant Failing Earlier Than Expected: What Facts Could Support an Exemplary-Damages Claim?
- A Breast Implant Claim Involving a Rare Lymphoma: What Facts Could Support an Exemplary-Damages Claim?
- An Insulin Pump Delivering an Incorrect Dose: Which Economic and Non-Economic Damages Could Be Available?